Frontlight ResearchEarly access
Familial hypercholesterolaemia trials in Poland
5 of 6 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 2/3Taking peopleA Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
- Where
- Gdansk, Lodz
- Age
- 6 years to 17 years
- People
- 153 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07058077 · EU 2024-519068-42-00 - Phase 3Taking peopleComparison of inclisiran or alirocumab to standard therapy in pediatric heterozygous familial hypercholesterolemia (HeFH) – the head-to-head PICOLO-FH clinical trial
- Where
- Gdansk, Lodz
- Age
- Up to 17 years
- People
- 400
- Run by
- Medical University Of Lodz
See details and how to join2024-514523-42-00 - Phase 3Taking peopleStudy of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
- Where
- Warsaw
- Age
- 12 years to 17 years
- People
- 10 worldwide
- Run by
- Arrowhead Pharmaceuticals
See details and how to joinNCT07473843 · EU 2025-523662-24-00 - Phase 3Active, not recruitingLong-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
- Where
- Gdansk, Lodz
- Age
- 2 years to 100 years
- People
- 195 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT05682378 - Phase 3Taking peopleStudy to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
- Where
- Bialystok, Gdansk, Lodz
- Age
- 6 years to 11 years
- People
- 60 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06597019